Innealta Capital’s TG Therapeutics TGTX Stock Holding History

Innealta Capital’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-41	Closed	-$730	–	1518
2024 Q2	$730	Buy	+41	New	+$654	﹤0.01%	1383

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Innealta Capital's TGTX Position: Q3 2024 in Review

Innealta Capital sold out of TG Therapeutics (TGTX) in Q3 2024, closing a stake of 41 shares — an estimated $730 sold.

Innealta Capital first reported a position in TGTX in Q2 2024 and held it in 1 quarter. The position peaked at $730 in Q2 2024. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

Innealta Capital reported no remaining TG Therapeutics position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 41 TG Therapeutics shares in Q3 2024, an estimated $730.
Innealta Capital first reported a position in TG Therapeutics in Q2 2024 and held it in 1 quarter.
Innealta Capital's TG Therapeutics position peaked at $730 in Q2 2024.
308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.